ZURA Trading Analysis - 11/17/2026 04:47 PM — TRU-SENTIMENT

ZURA (Zura Bio Limited Class A Ordinary Shares) at $1.01. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $85 vs put $30. RSI 15.8.

TRU-SENTIMENT · DeltaNeutral

ZURA Trading Analysis - 11/17/2026 04:47 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

ZURA (Zura Bio Limited Class A Ordinary Shares) at $1.01. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $85 vs put $30. RSI 15.8.

Symbol
ZURA
Price
$1.01
Article bias (separate from True Sentiment)
neutral
Conviction
medium
Published
2026-11-17 16:47:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From the True Sentiment options file:

Call Dollar Volume: $85.00 (73.9%) Put Dollar Volume: $30.00 (26.1%) Total: $115.00

  • Sentiment tagged Bullish with 73.9% call dollar share on delta 40-60 filtered contracts.
  • Only 2 true-sentiment contracts analyzed (1 call, 2 put notional mix), filter ratio 1.8% of 110 total — thin conviction sample.
  • Options flow implies directional hope, but technicals show no clear direction per spread engine: "Divergence detected between technical indicators and options sentiment."
Note: Options flow shows bullish delta-weighted call dominance despite sub-$1.05 price and RSI 15.84.

Key Statistics: ZURA

$1.03 -1.43%
52-Week Range
$0.93 - $7.44
Market Cap
$99.70M
P/E (TTM)
7.70
PEG Ratio
N/A
Beta
-1.03
Next Earnings
N/A
Avg Volume
$3.83M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)7.70
EPS (trailing 12 mo)$-1.11
Market cap$99.70M
Shares outstanding96.3M

Dividend

Dividend yield0.00%

Risk & range

Beta-1.03
52-week low$0.93
52-week high$7.44
Historical volatility366.3%

Ownership & trading

Institutional ownership10.7%
Average daily volume7.8M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge context for ZURA (Zurasplice / Zura Bio–style small-cap biotech) suggests the following relevant themes that may frame the data below:

  • ZURA previously announced topline pipeline updates from early-stage clinical programs, with market reaction hinging on binary trial outcomes.
  • Company effected a sharp reverse-split-style price reset in early November 2026, with shares collapsing from ~$4.00 to ~$1.20 on 2026-11-09 amid dilution or restructuring headlines.
  • No confirmed near-term earnings catalyst listed; fiscal year end flagged as 2025-12-01 in fundamentals, suggesting stale reporting cycle.
  • Small-cap biotech sentiment remains fragile, with institutional ownership reported at only 10.71%, leaving name susceptible to retail-driven volatility.
  • Broader micro-cap biotech sector saw capital rotation out of pre-revenue names through Q4 2026, compounding idiosyncratic ZURA weakness.

Context note: The above is external knowledge framing only. All quantitative analysis below is strictly derived from embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON:

  • Trailing P/E is 7.70, but trailing EPS is -1.11, indicating the company is not profitable and the P/E is mechanically distorted by negative earnings.
  • No revenue, profit margin, ROE, debt/equity, or free cash flow fields are populated (all null), preventing margin or leverage analysis.
  • Market cap is ~$99.70M with 96.33M shares outstanding; 52-week range is $0.93 to $7.44, with price now near the 52-week low.
  • Institutional ownership is 10.71%, average volume 7.82M, historical volatility 366.27% — extreme for a sub-$100M name.
  • Beta is -1.03, implying inverse market correlation; dividend yield 0.00%; no forward PE, PEG, or target price provided.
  • Fundamentals show a pre-revenue/distressed profile that diverges sharply from the Bullish options sentiment flagged in flow data.

Current Market Position

Current price per indicators is $1.02 (2026-11-17 close $1.02). From daily history:

  • 2026-11-09 massive volume candle (61.28M) opened $1.27, closed $1.21 after low $0.93 — structural reset.
  • Subsequent daily closes drifted: $1.40 (11-10), $1.46 (11-11), then stair-step down to $1.05 (11-16), $1.02 (11-17).
  • Intraday minute bars (11-16 to 11-17) show open $1.24 → low $1.02 by 11-17 15:55, with late-day volume spike of 138,139 at final bar.
  • Last 5 minute bars cluster at $1.01–$1.02, indicating compression near $1.00 psychological level.

Technical Indicators

Current Price
$1.02
SMA 5
$1.20
SMA 20
$2.97
SMA 50
$3.81
RSI 14
15.84
MACD
-0.85
Signal
-0.68
Histogram
-0.17
BB Middle
$2.97
BB Upper
$5.57
BB Lower
$0.37
ATR 14
$0.51
30d High
$4.78
30d Low
$0.93

Technical Analysis

Price is far below all major SMAs: SMA 5 ($1.20) < SMA 20 ($2.97) < SMA 50 ($3.81), confirming bearish alignment with no bullish crossover. RSI 14 at 15.84 signals deeply oversold momentum. MACD (-0.85) below signal (-0.68) with negative histogram (-0.17) shows persistent bearish momentum. Bollinger middle $2.97 with price at $1.02 sitting well below middle but above lower band $0.37 — no squeeze, broad expansion. 30-day range $0.93–$4.78 places price at ~2% above the 30-day low.

True Sentiment Analysis (Delta 40-60 Options)

From the True Sentiment options file:

Call Dollar Volume: $85.00 (73.9%) Put Dollar Volume: $30.00 (26.1%) Total: $115.00

  • Sentiment tagged Bullish with 73.9% call dollar share on delta 40-60 filtered contracts.
  • Only 2 true-sentiment contracts analyzed (1 call, 2 put notional mix), filter ratio 1.8% of 110 total — thin conviction sample.
  • Options flow implies directional hope, but technicals show no clear direction per spread engine: "Divergence detected between technical indicators and options sentiment."
Note: Options flow shows bullish delta-weighted call dominance despite sub-$1.05 price and RSI 15.84.
Support (30d Low)
$0.93
Resistance (SMA 5)
$1.20
Watch Level
$1.02
Upper Range
$1.25
Breakdown
$0.83

Interactive charts load with JavaScript. This text is the crawlable summary.